Sangamo Therapeutics, Inc.
SGMO
$0.6223
-$0.0309-4.73%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -84.72% | 13,779.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -84.72% | 13,779.78% | |||
| Cost of Revenue | -14.63% | 11.72% | |||
| Gross Profit | -174.37% | 188.61% | |||
| SG&A Expenses | 12.91% | -41.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.08% | -8.05% | |||
| Operating Income | -298.68% | 133.23% | |||
| Income Before Tax | -321.40% | 129.84% | |||
| Income Tax Expenses | -585.23% | 18.92% | |||
| Earnings from Continuing Operations | -319.23% | 129.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -319.23% | 129.54% | |||
| EBIT | -298.68% | 133.23% | |||
| EBITDA | -272.99% | 137.53% | |||
| EPS Basic | -347.33% | 126.35% | |||
| Normalized Basic EPS | -278.48% | 133.76% | |||
| EPS Diluted | -389.75% | 123.42% | |||
| Normalized Diluted EPS | -283.59% | 132.82% | |||
| Average Basic Shares Outstanding | 0.88% | 2.16% | |||
| Average Diluted Shares Outstanding | -1.93% | 5.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
